A 52-year-old man with a 10-year history of Major Depressive Disorder presents with persistent depressed mood, fatigue, and concentration difficulties despite adequate trials of sertraline (200 mg/day × 8 weeks) and escitalopram (20 mg/day × 8 weeks). He denies suicidal ideation. Physical examination and routine laboratory investigations (TSH, vitamin B12, folate) are normal. He has been compliant with medications as verified by pill counts. What is the most appropriate next step in management?

Explanation

## Treatment of Treatment-Resistant Depression (TRD) **Key Point:** This patient has **treatment-resistant depression (TRD)**, defined as failure to achieve remission after ≥2 adequate trials of antidepressants from different classes at therapeutic doses for ≥4–6 weeks each. ### Diagnostic Criteria for TRD Met - Sertraline 200 mg/day × 8 weeks (SSRI trial) — adequate - Escitalopram 20 mg/day × 8 weeks (another SSRI trial) — adequate - Confirmed medication adherence (pill counts) - Exclusion of medical causes (normal TSH, B12, folate) - No suicidal ideation (not an immediate safety crisis) ### Evidence-Based Management Algorithm for TRD ```mermaid flowchart TD A[TRD Confirmed<br/>2 failed SSRI trials]:::outcome --> B{Next Step?}:::decision B -->|Optimize current dose| C[Increase SSRI to max<br/>or switch SSRI class]:::action B -->|Augmentation| D[Add atypical antipsychotic<br/>aripiprazole/risperidone]:::action B -->|Switch class| E[TCA or SNRI]:::action B -->|Severe/urgent| F[ECT consideration]:::urgent D --> G[Aripiprazole 5-15 mg/day<br/>or Risperidone 2-6 mg/day]:::action G --> H[Response in 2-4 weeks]:::outcome ``` **High-Yield:** **Augmentation with atypical antipsychotics** (aripiprazole, risperidone, quetiapine) is the most evidence-supported next step in TRD after 2 failed monotherapy trials. Meta-analyses show response rates of 50–60% with augmentation. ### Why Augmentation with Aripiprazole? - Robust evidence from multiple RCTs (FDA-approved for TRD augmentation) - Mechanism: dopamine D2 antagonism enhances serotonergic neurotransmission - Starting dose: 5 mg/day, titrate to 10–15 mg/day - Response typically seen within 2–4 weeks - Fewer metabolic side effects than risperidone or quetiapine **Clinical Pearl:** Augmentation is preferred over switching to a third monotherapy because the patient has already failed two agents; adding a synergistic mechanism (antipsychotic) is more efficient than a third sequential trial. ### Comparison of Next-Step Options | Approach | Evidence | Timing | Indication | |----------|----------|--------|------------| | Increase SSRI dose | Weak for TRD | 4–6 weeks | Only if dose suboptimal | | Switch to TCA | Moderate | 6–8 weeks | If augmentation fails | | Augment with atypical AP | Strong (FDA-approved) | 2–4 weeks | **First-line for TRD** | | ECT | Very strong | Immediate | Severe/psychotic/catatonic/suicidal | **Mnemonic:** **TRAD** = Treatment-Resistant Antidepressant Disorder → **Try Robust Augmentation Drugs** (atypical antipsychotics).